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ABSTRACT
Introduction: The purpose of this study was to
describe healthcare resource utilization and
costs resulting from early (within 30 days of
diagnosis) versus late ([30 days after diagnosis)
treatment with prescriptions for H.P. Acthar
Gel (repository corticotropin injection; Acthar;
Mallinckrodt) to manage infantile spasms (IS).
Methods: We included all patients in the
Truven Health MarketScan Commercial
Claims and Encounters Database and the
Truven Health MarketScan Multi-State
Medicaid Database who were diagnosed with
IS from 2007 to 2012. We performed unadjusted
and adjusted regressions examining the
relationship between healthcare resource
utilization variables and their associated costs
to compare outcomes in the early and late
Acthar users.
Results: A total of 252 patients with IS who
received Acthar fit our study criteria; 191 (76%)
were early Acthar users. In adjusted analyses, we
found that early Acthar use was associated with,
on average, 3.8 fewer outpatient services (99%
CI 0.7–6.7 fewer services). We did not find
significant associations between early
prescriptions for Acthar and number of
hospitalizations, emergency room visits,
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prescription medications filled, or total costs of
health services.
Conclusion: Patients prescribed Acthar within
30 days of their IS diagnoses tended to have
fewer outpatient services performed compared
to patients prescribed Acthar later in the disease
process. Although additional research is needed
to confirm these exploratory findings,
physicians may consider early treatment with
Acthar to manage IS.
Funding: This study was funded by a grant to
the University of Washington from
Mallinckrodt Pharmaceuticals.
Keywords: Costs; Healthcare resource
utilization; H.P. Acthar Gel (repository
corticotropin injection); Infantile spasms;
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INTRODUCTION
Infantile spasms (IS; West syndrome) is a rare
(occurring in about 1.6–4.5/10,000 live births)
[1–4], but often devastating form of epilepsy
that typically occurs in the first year of life [2].
Although spasms usually resolve by age five, the
long-term prognoses of infants diagnosed with
IS are relatively poor, with the majority of
patients developing conditions, such as
refractory epilepsy, mental retardation, and
autistic spectrum disorders [2, 5–9]. While the
therapeutic response and complete resolution
of IS largely depend on the underlying etiology
and other clinical factors, early diagnosis and
prompt treatment may improve neurological
and developmental outcomes [2, 9, 10].
In the US, hormonal therapies, such as
intramuscular adrenocorticotropic hormone
(ACTH), are commonly used to treat IS; a
recent survey of clinicians treating IS reported
that 84% prescribed ACTH [11]. However, only
two drugs have received US Food and Drug
Administration (FDA) approval to treat IS: the
gamma-aminobutyric acid transaminase
inhibitor vigabatrin (Sabril; Lundbeck) [12]
and H.P. Acthar Gel (repository corticotropin
injection; Acthar; Mallinckrodt) [13]. Following
treatment, infants typically undergo
electroencephalograms (EEGs) to evaluate
treatment effectiveness, which is defined as
both complete cessation of spasms as well as
the resolution of hypsarrhythmia on EEGs [2]
and, if indicated, treatments are modified [5].
Although analysis of healthcare resource
utilization in patients with convulsive
disorders is the starting point for economic
assessment of the medical burden of these
conditions, little research has been
conducted. The purpose of this study was to
describe health outcomes and costs resulting
from early (within 30 days of diagnosis)
prescriptions of Acthar versus later (more
than 30 days after diagnosis) prescriptions to
generate hypotheses for future studies on
healthcare utilization and treatment patterns
among patients with IS.
METHODS
Study Population and Data Source
We used the Truven Health MarketScan
Commercial Claims and Encounters Database
and the Truven Health MarketScan Multi-State
Medicaid Database to identify the study cohort.
These databases contained inpatient,
outpatient, pharmacy claims, and insurance
coverage data for patients across the US who
are enrolled in commercial insurance plans. The
inpatient and outpatient claims databases
include procedure and visit-level details from
medical claims, such as the International
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Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) diagnosis
and procedure codes, Current Procedural
Terminology (CPT) medical procedure codes,
dates of service, and variables describing
financial expenditures. The pharmacy claims
database provided details, including National
Drug Codes (NDC), dates dispensed, quantity
and days’ supply, and payments made for each
claim. A separate eligibility and demographics
file provided additional information about each
subject, such as age, gender, insurance plan
type, geographic location, and enrollment
status by month.
We included patients in the MarketScan
Research Database who received treatment for
IS (ICD-9-CM diagnosis code: 345.60) between
April 1, 2007 and December 31, 2012 who were
less than 2 years old at the time of the IS
diagnosis. This age restriction is aligned with
the US FDA’s labeled indication for Acthar [14].
Patients with subsequent diagnoses of tuberous
sclerosis complex (TSC; ICD-9-CM diagnosis
code: 759.5) were excluded from our analyses.
TSC is a complex genetic disorder that can affect
multiple organs and is usually treated
effectively with vigabatrin or surgery [15]. To
have complete comorbidity and health
outcome data, we also excluded patients who
were not enrolled in their health plans
continuously for at least 3 months prior and
12 months after the index date.
We classified patients in our study cohort
who had outpatient prescriptions or procedure
codes indicating the receipt of prescriptions for
Acthar (NDCs: 63004-77310-1, 63004-87100-1;
CPT code: J0800) into those who received
Acthar prescriptions early (within 30 days of
the index IS incident) and those who received
Acthar prescriptions later (more than 30 days
after the index IS incident). Patients who
received prescriptions for Acthar within
30 days and, in addition, received
prescriptions for Acthar more than 30 days
after their index diagnoses were included in
the early Acthar group. We assumed the
subsequent prescriptions for Acthar were likely
to be continuations of therapies that began
within 30 days.
The MarketScan Research Database
contained patient demographic variables,
including age, gender, type of health
insurance plan (types of private plans and
Medicaid versus non-Medicaid), and
geographic region (although region data were
not available for patients with Medicaid). We
also assessed year of IS diagnosis and the
number of outpatient services,
hospitalizations, and medications filled in the
90 days prior to index IS incident. In addition,
we also looked for use of anticonvulsants,
steroids, or vigabatrin (Sabril) prior to receipt
of Acthar prescriptions (see Table S1 in the
supplementary material for a complete list of
these medications), previous diagnoses of major
cardiac diseases, central nervous system
malformations, and severe metabolic
conditions (see Table S2 in the supplementary
material for a complete list of the ICD-9-CM
diagnosis codes included in each of these
categories).
Statistical Analysis
We calculated proportions and Chi-square
tests (for categorical variables) and means,
standard deviations, and t tests (for
continuous variables) of factors that might
have been related to health costs and
outcomes and early receipt of Acthar
prescriptions. Variables with P values of
B0.05 were considered significant
confounders. Next, we calculated means,
medians, ranges, standard deviations, and
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differences between means of each healthcare
utilization and cost among patients who
received early Acthar prescriptions compared
to patients who received late Acthar
prescriptions. Because we made multiple
comparisons (n = 15), we determined that
P values of 0.01 would represent statistically
significant associations between receipt of
early Acthar prescriptions and each
utilization or cost outcome. We calculated
adjusted means and adjusted differences
between means. For outcomes with count
variables, we used generalized linear
regression with log links and specified the
Poisson distribution to calculate adjusted
means and 99% confidence intervals (CIs).
For the binary outcome of whether patients
were readmitted to the hospital within 30 days
of discharge, we used logistic regression to
calculate odds ratios (ORs) and 99% CIs. For
cost outcomes, we used generalized linear
regressions with log links and specified the
gamma distribution to calculate adjusted
means and 99% CIs. To allow cost models to
run, nominal amounts were added to patients
with zero costs. Because the inclusion of
covariates in the adjusted models affected
the estimates of component costs, individual
cost components did not add exactly to the
adjusted total costs.
SAS for Windows, version 9.3 (SAS Institute,
Inc., Cary, NC, USA) was used for all analyses.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, revised in 2013.
This study was exempt from review by the
University of Washington Institutional Review
Board (IRB) through self-determination.
RESULTS
Out of 108,860,485 individuals enrolled in the
MarketScan and Medicaid databases between
April 1, 2007 and December 31, 2012, a total of
5158 patients with IS were identified (Fig. 1). Of
these, 201 patients were excluded, because they
had subsequent diagnoses of tuberous sclerosis,
and 1949 patients were excluded, because they
were not enrolled for at least 3 months before
and 12 months after their initial IS diagnoses.
We also excluded 2000 patients, because their
ages were missing or they were not less than
2 years old at the time of their IS diagnoses. Of
the remaining 1008 patients, 756 were
excluded, because they did not receive
prescriptions for Acthar. Of the 252 patients
with IS who received prescriptions for Acthar,
191 (76%) were prescribed Acthar within
30 days or less.
Demographic characteristics of patients who
received prescriptions for Acthar are shown in
Table 1. A smaller proportion of early Acthar
prescription recipients were female compared to
male (39% versus 61%; P = 0.03). A higher
proportion of patients who received Acthar
later filled prescriptions for anticonvulsants
prior to filling prescriptions for Acthar (21%
versus 33%; P = 0.07). In addition, higher
proportions of patients who received Acthar
later had been diagnosed with severe central
nervous system malformations prior to being
diagnosed with IS (14% versus 31%; P = 0.002).
Patients who were prescribed Acthar early had
fewer hospitalizations in the 90 days prior to
the IS diagnosis compared to patients who were
prescribed Acthar later (0.2 versus 0.6;
P = 0.0002). Patients who were prescribed
1296 Adv Ther (2016) 33:1293–1304
Acthar early were similar to those who were
prescribed Acthar later in terms of age,
insurance plan, geographic region, and year of
IS diagnosis, whether they filled prescriptions
for steroids prior to filling prescriptions for
Acthar, whether they had diagnoses of major
cardiac diseases or metabolic conditions, and
the number of outpatient services and
Fig. 1 Study participant ﬂow
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Table 1 Characteristics of infantile spasm patients prescribed Acthar within 30 days of index diagnosis compared to
patients prescribed Acthar more than 30 days after diagnosis
Characteristics Acthar Rxa (£30 days post-index)
n5 191 (76%)
Acthar Rxa (>30 days post-index)
n5 61 (24%)
P valueb
Age (years), mean (SD) 0.62 (0.49) 0.64 (0.48) 0.76
Age 0 to\1 year 73 (38%) 22 (36%) 0.76
Age 1 to\2 years 118 (62%) 39 (64%)
Female 74 (39%) 33 (54%) 0.03
Male 117 (61%) 28 (46%)
Non-Medicaid 154 (81%) 49 (80%) 0.96
Medicaid 37 (19%) 12 (20%)
Type of health plan
Comprehensive 18 (9%) 9 (15%) 0.42
Exclusive/preferred provider
organization
93 (49%) 32 (52%)
Health maintenance
organization
46 (24%) 9 (15%)
Point of service 19 (10%) 7 (11%)
Consumer-directed/
high-deductible
15 (8%) 3 (5%)
Missing 0 (0.0%) 1 (1%)
Geographic region
Northeast 27 (14%) 9 (15%) 0.82
North Central 46 (24%) 13 (21%)
South 51 (27%) 16 (26%)
West 25 (13%) 11 (18%)
Missingc 42 (22%) 12 (20%)
Year of IS incident
2007 29 (15%) 7 (11%) 0.19
2008 35 (18%) 21 (34%)
2009 34 (18%) 8 (13%)
2010 35 (18%) 11 (18%)
2011 30 (16%) 8 (13%)
2012 28 (15%) 6 (10%)
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medications in the 90 days prior to diagnosis.
No patients received vigabatrin prior to
receiving prescriptions for Acthar.
In unadjusted analyses (Table 2), we found
that patients who were prescribed Acthar within
30 days of diagnosis had non-statistically
significantly reduced outpatient services (12
fewer procedures; 99% CI -29 to 3.7), fewer
inpatient, outpatient, and medication fills
combined (18 fewer health services; 99% CI
-40 to 3.9), and similar costs. The two groups
were similar in terms of number of
hospitalizations, mean length of stay per
hospitalization, number of admissions to the
intensive care unit, readmissions within
30 days, emergency room visits,
hospitalization costs, and total costs.
Following adjustment for gender, comorbid
diagnoses of central nervous system disorders,
and hospitalizations in the 90 days prior to the
IS diagnosis (Table 3), the association between
early Acthar prescriptions and the number of
outpatient services became statistically
significant (3.8 fewer outpatient procedures;
99% CI -6.7 to -0.7) as did the reduced
number of total health services (4.2 fewer total
health services; 99% CI -7.9 to -0.4). We also
found that, among patients who had at least
one hospitalization, those who received Acthar
early were almost twice as likely to have been
readmitted within 30 days, though not
statistically significantly (99% CI 0.7 to 5.0).
Table 1 continued
Characteristics Acthar Rxa (£30 days post-index)
n5 191 (76%)
Acthar Rxa (>30 days post-index)
n5 61 (24%)
P valueb
Rx ﬁlled prior to IS diagnosisd
Steroid 11 (6%) 6 (10%) 0.27
Anticonvulsant 41 (21%) 20 (33%) 0.07
Vigabatrin 0 (0.0%) 0 (0.0%) –
Comorbidities diagnosed prior to IS diagnosise
Major cardiac diseases 43 (23%) 19 (31%) 0.17
Metabolic conditions 17 (9%) 6 (10%) 0.83
Severe central nervous system
malformations
26 (14%) 19 (31%) 0.002
Number of utilizations from days -90 to -1, mean ± SD (range)
Outpatient services 10.2 ± 9.6 (0–54) 12.5 ± 9.5 (1–38) 0.12
Hospital admissions 0.2 ± 0.5 (0–2) 0.6 ± 1.0 (0–4) 0.0002
Medications 3.5 ± 4.9 (0–31) 4.0 ± 4.4 (0–19) 0.54
Rx prescription, SD standard deviation
Values are given as n (%) unless otherwise stated
a Patients could have had both early and late Acthar Rx (n = 63)
b P value calculated using t test for continuous variables or Chi-square test for categorical variables
c Region data missing from patients in Medicaid database
d See Table S1 for list of National Drug Codes and generic names of each type of medication
e See Table S2 for list of International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation diagnosis codes of
each type of comorbidity
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DISCUSSION
The majority of the patients with IS in our
cohort were prescribed Acthar within 30 days of
their IS diagnoses. Relative to patients who were
prescribed Acthar more than 30 days after
diagnosis, the patients prescribed Acthar
earlier had fewer outpatient procedures
performed. In spite of this reduction in
utilization, total costs were similar between
the two groups, possibly because the group
that received Acthar early had similar numbers
of expensive utilizations, such as emergency
department visits and inpatient stays. The fact
that we observed a two-fold increase in the odds
of 30-day readmissions among patients who
received Acthar earlier supports this hypothesis.
Although associations between the timing of
IS treatment and healthcare utilization and
costs have not been well studied, previous
research has shown that earlier treatment is
associated with improved developmental
outcomes [10]. One study showed that earlier
treatment for IS significantly improved patients’
Vineland Adaptive Behavior Scale (VABS)
scores, which measured patients’ ability to
cope with environmental changes,
demonstrate independence, and learn new
skills [16]. Another study indicated that
neurodevelopmental outcomes are better for
infants who have shorter duration of spasms
and, therefore, shorter times of epileptic
encephalopathy [17]. Our study contributes to
evidence that earlier treatment for IS may also
be beneficial to achieve less healthcare
utilization and lower medication burden.
This study had several limitations. First,
exposure to Acthar was predominantly
identified through outpatient prescription fills,
thus it is possible that some patients were
subject to misclassification, because the
medication was not actually administered.
However, given that Acthar is a brand name
medication that is usually accompanied with a
portion of patient cost-sharing, and that we
observed patients with multiple prescription
fills, we are reassured that the majority of
patients with Acthar prescription claims
actually received the medication. In addition,
because this was an observational study and not
a randomized control trial, we cannot be certain
that the differences we observed between
patients who were prescribed Acthar early
versus later could not be explained by
confounding factors. We attempted to correct
for this by adjusting our models for potentially
confounding variables, but unmeasured factors
might play a role in the associations that we
reported. Because we were interested in
outcomes that occurred over the 12 months
after the index IS diagnosis, we excluded
patients who were not enrolled in their health
plans for 1 year after the index event, so our
population was stable by definition, and our
results are likely not generalizable to more
transient populations. We also did not have
information on procedures or healthcare
resource utilization for which patients paid
out-of-pocket rather than filing claims through
their insurance companies, and our cost
estimates might, therefore, be conservative.
Furthermore, the population of patients in the
MarketScan databases is not randomly sampled
and some populations, such as patients insured
by small employers, were not represented in this
study population. Therefore, these results may
not be generalizable across all patients with IS in
the US. Finally, we were unable to account for
potential lag times from initial IS symptoms
until definitive diagnoses were observed in the
claims data. Patients who had been
experiencing symptoms for substantial periods
of time before their IS diagnosis may have been
erroneously placed in the ‘‘early’’ treatment
1302 Adv Ther (2016) 33:1293–1304
category, when in reality, their treatments
could have been delayed if measured from the
time that their symptoms first occurred. These
unmeasured delays likely would have impacted
healthcare utilization and costs for these
patients.
CONCLUSIONS
In summary, we determined that earlier
prescribing of Acthar to treat IS was associated
with fewer outpatient procedures compared to
later prescribing of this drug. Future studies
should expand upon this descriptive work by
focusing on analyzing long-term neurological
outcomes both among patients who are
prescribed Acthar early versus later, as well as
examining outcomes among patients who are
prescribed Acthar compared to other IS
treatments.
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